Basosquamous carcinoma and metatypical basal cell carcinoma: a review of treatment with Mohs micrographic surgery

Abstract

BSC and MBCC showed no significant distinguishing characteristics to separate them into two BCC subtypes. Reported recurrence rates for BSC and MBCC are 12-45% with wide local excision; estimated recurrence rates are 4.1% with MMS. Our study showed recurrence-free survival of 95.1% at five years. Hence, MMS is effective in treating these BCC subtypes.

Basal cell carcinoma: Epidemiology, clinical and histologic features, and basic science overview

“…Another instance that can mimic this tumor is when one finds a collision tumor with BCC and cSCC components 37 . If correctly identified, metatypical BCCs are associated with increased recurrences and even distant metastases [56][57][58] . Occurrence of cSCC among patients receiving this therapy was recently reported [67][68][69] .…”

Cells to Surgery Quiz: December 2019

“…Mohs micrographic surgery provides the highest rate cure. The standard therapy for BSC is Mohs micrographic surgery (Allen et al, 2014;Leibovitch et al, 2005a;Skaria, 2010). Mohs micrographic surgery reduces the recurrence rate of BSC to about 4 e9% (Wermker et al, 2015).…”

The collision tumor in the assessment of non‐melanoma skin cancer caused by occupational UV exposure

“…Zwei klonal unterschiedliche und räumlich separierte Neoplasien entwickeln sich eigenständig in enger Nachbarschaft zueinander, wachsen aufeinander zu und "kollidieren" im Verlauf [9][10][11]. Damit ist der Kollisionstumor differenzialdiagnostisch vom basosquamösen Karzinom abzugrenzen, das ein Basalzellkarzinom mit fragmentarischer Differenzierung zu einem Plattenepithelkarzinom bezeichnet und teils synonym mit den mittlerweile veralteten Begriffen des "metaplastischen" oder "metatypischen" Basalzellkarzinoms verwendet wird [12]. Da eine Differenzierung allein anhand der Klinik nicht möglich ist, sind neben histopathologischen ergänzende immunhistochemische Untersuchungen unabdingbar.…”